Forward-Looking Information
This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, the Company’s ability to expand its product offerings to include concentrates and edibles in Massachusetts and Pennsylvania and to add meaningful wholesale revenue the success of TILT’s brand strategy, the receipt of any regulatory approvals, the anticipated growth of cannabis markets, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT.
CAC”). The Company intends to begin cultivation operations in the newly approved space later this month.
“We are pleased to announce the regulatory approval of the second phase of the planned expansion of our 117,000 sq ft cultivation and manufacturing facility in Taunton, Massachusetts,” said
Gary Santo, president of TILT. “We now have more than 56,000 sq. ft. of cultivation space with the ability to add a second grow tier to each of the eight new rooms, pending regulatory approval. Once planted, these additional rooms will fortify the supply of premium flower for our Taunton dispensary, and together with our award-winning kitchen and state-of-the art extraction and processing lab, will support the production and distribution of high-quality, consistent products for our brand partners. As we continue to solidify CAC’s presence in the state, we remain committed to working with the CCC to achieve final state licenses permitting medical dispensary operations at our Brockto
)
(OTCQX: TLLTF), a provider of business solutions to the global cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development, distribution and retail, announced preliminary financial results and operational highlights for the fourth quarter ended December 31, 2020 (“Q4 2020”) and full year outlook for 2021. All financial information is unaudited and provided in U.S. dollars except where otherwise indicated.
Projected Preliminary Financial Highlights:
Q4 2020 revenue is projected to be between $42.2 million and $43.2 million, compared to Q3 2020 revenue of $40.4 million
Q4 2020 Adjusted EBITDA is projected to be between $2.6 million and $3.6 million, compared to Q3 2020 Adjusted EBITDA of $2.8 million
Pro-forma Q4 2020 revenue excluding the Company’s former subsidiary, Blackbird, is projected to be between $41.3 million and $42.3 million, compared to Q3 2020 pro-forma revenue of $39.1 million
Earlier this month, the Commonwealth Dispensary Association (“
CDA”) filed a lawsuit against the
Cannabis Control Commission related to new delivery regulations that would benefit social equity and economic empowerment operators. Commonwealth Alternative Care (“
CAC”), a wholly owned subsidiary of
TILT”) and a member of the CDA, has been clear in expressing its concerns regarding the possibility of filing such a suit and is extremely disappointed in the CDA’s decision to pursue litigation.
TILT firmly believes that social equity operators can and must be a vital part of the cannabis ecosystem and while there is always room for improvement with newly drafted regulations, we do not think that engaging in litigation achieves any such improvement.